Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

Elizabeth Walter, Philip D. Greenberg, M. Jean Gilbert et al. · New England Journal of Medicine · 1995 · 1.8K citations

Life Sciences, Hematology, Immunology +13

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Zelig Eshhar, Tova Waks, G. Gross et al. · Proceedings of the National Academy of Sciences · 1993 · 1.6K citations

Life Sciences, Immunology, Oncology +17